Complete Response of Advanced Hepatocellular Carcinoma with Multiple Lung Metastases Treated with Sorafenib: A Case Report
Complete Response of Advanced Hepatocellular Carcinoma with Multiple Lung Metastases Treated with Sorafenib: A Case Report
复制标题
DOI：
10.1159/000333279
复制
发表时间：
2011-01-01
期刊：
影响因子：
3.5
通讯作者：
Kudo, Masatoshi
中科院分区：
文献类型：
--
作者：
Inuzuka, Tadashi;Nishikawa, Hiroki;Kudo, Masatoshi
索拉非尼是一种口服多激酶抑制剂，已证明对晚期肝细胞癌 (HCC) 患者具有临床疗效。然而，在SHARP试验（索拉非尼HCC评估随机方案试验）和亚太试验（在亚太地区进行）中，没有报告完全缓解（CR）的病例。此后，全球范围内仅报告了相对少量的索拉非尼治疗 CR 病例。我们在此报告一例接受索拉非尼治疗 4 个月的患者出现 CR 的病例。该患者患有晚期HCC，伴有多发肺转移，停药8个月后未见复发。据我们所知，这是首次单独接受索拉非尼治疗 HCC 的女性获得 CR。版权所有 (C) 2011 S. Karger AG，巴塞尔
Sorafenib, an oral multikinase inhibitor, has demonstrated clinical efficacy in patients with advanced hepatocellular carcinoma (HCC). However, in the SHARP trial (Sorafenib HCC Assessment Randomized Protocol trial) and the Asia-Pacific trial (conducted in the Asia-Pacific region), no cases of complete response (CR) were reported. Thereafter, only a relatively small number of CR cases were reported worldwide for sorafenib therapy. We herein report a case of CR in a patient treated with sorafenib for 4 months. The patient had advanced HCC with multiple lung metastases, and there has been no recurrence after 8 months following cessation of administration. To our knowledge, this is the first time a female treated with sorafenib alone for HCC has had a CR. Copyright (C) 2011 S. Karger AG, Basel